Pharma & Biotech Events & Conferences
Refine Search
Biotechnology
Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it released early-stage data on its FT819 in lupus. 19 November 2024
Pharmaceutical
US clinical-stage biopharmaceutical company Boston Pharmaceuticals has announced positive results from a Phase II study evaluating the safety and efficacy of once-monthly efimosfermin alfa (formerly known as BOS-580), a long-acting FGF21 analogue, in participants with stage F2/F3 fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH). 18 November 2024
Pharmaceutical
French drugmaker Ipsen today announced the long-term efficacy and safety of patients treated with Bylvay (odevixibat) from two Phase III open-label extension studies. 18 November 2024
Pharmaceutical
US antiviral giant Gilead Sciences on Friday unveiled two-and-a-half-year interim analysis from the ongoing Phase III ASSURE study of its Livdelzi (seladelpar). 16 November 2024
Pharmaceutical
French drugmaker Ipsen announced late-breaking data for Iqirvo (elafibranor 80mg tablets) from an interim analysis of the ongoing open-label extension of the Phase III ELATIVE study at the American Association for the Study of Liver Disease (AASLD) congress. 16 November 2024
Biotechnology
Belgian drugmaker UCB and US biotech Biogen’s Phase III PHOENYCS GO trial results signal a pivotal development for systemic lupus erythematosus (SLE) treatment, as dapirolizumab pegol met its primary endpoint and demonstrated enhanced disease control and safety at Week 48. 13 November 2024
Biotechnology
Syndax Pharmaceuticals has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib achieved its primary endpoint. 13 November 2024
Pharmaceutical
Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data for its investigational medicine VK2738 at the ObesityWeek meeting. US biotech Beam Therapeutics released early-stage data on its sickle cell disease candidate BEAM-101. Also of note, Arcus Biosciences and Gilead Sciences announced promising Phase III results for their TIGIT inhibitor domvanalimab in combination with zimberelimab. Denmark’s Novo Nordisk released financial results that attracted interest. 10 November 2024
Biotechnology
Shanghai-based BioCity Biopharma has announced promising late-stage results from the Phase II 2-SUCCEED clinical trial of SC0062. 7 November 2024
Biotechnology
Results from the ARC-10 Phase III study of Arcus Biosciences and Gilead Sciences’ domvanalimab and zimberelimab combination therapy indicate a significant reduction in mortality risk for patients with certain advanced lung cancers. 7 November 2024
Biotechnology
Beam Therapeutics will detail new clinical and preclinical data on its sickle cell disease (SCD) therapies at the upcoming American Society of Hematology (ASH) meeting. 6 November 2024
Pharmaceutical
AstraZeneca has presented early results on three experimental weight-loss drugs at the ObesityWeek conference in San Antonio, showing encouraging signs for its obesity pipeline. 5 November 2024
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 Psych Congress in Boston. 5 November 2024
Pharmaceutical
Viking Therapeutics (Nasdaq: VKTX) reported promising early results for its experimental obesity pill, VK2735, with increased weight loss at higher doses. 4 November 2024
Pharmaceutical
The US subsidiary of Israel’s Teva Pharmaceutical Industries has announced new, positive data on social functioning and quality of life from the Phase III subcutaneous olanzapine extended-release injection study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia. 2 November 2024
Biotechnology
UCB has reported Phase IIa data from the TOGETHER (AH0003) study, investigating the safety, efficacy, and tolerability of bepranemab - an investigational anti-tau antibody targeting the mid-region of the tau protein - in people living with prodromal to mild Alzheimer’s disease. 1 November 2024
Biosimilars
The US unit of South Korea-based biosimilar drug developer Celltrion
has announced a late-breaking post hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of Zymfentra (infliximab-dyyb), during the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting. 30 October 2024
Biotechnology
US pharma major Eli Lilly has released results from two, multi-year, Phase III studies that showed patients treated with mirikizumab sustained stable, long-term remission across two types of inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn’s disease. 28 October 2024
Biotechnology
California’s Vera Therapeutics has released 96-week follow-up results from its ORIGIN Phase IIb trial of atacicept, targeting IgA nephropathy (IgAN). 28 October 2024
Biotechnology
Swiss Pharma giant Novartis (NOVN: VX) has announced positive new data about Zolgensma (onasemnogene abeparvovec), an essential, one-time treatment and the only gene therapy for spinal muscular atrophy (SMA), from two clinical trials including the completed two-copy cohort of the Phase III SPR1NT clinical trial that demonstrates age-appropriate development when used pre-symptomatically and rapid, clinically meaningful efficacy in symptomatic children, even those with severe SMA at baseline, as well as and the completed Phase III STR1VE-EU trial which demonstrated rapid improvements in motor function following treatment with Zolgensma. 18 June 2021
Pharmaceutical
Ireland-incorporated Avadel Pharmaceuticals has announced new post hoc analyses of data from the completed pivotal Phase III REST-ON clinical trial of FT218, at SLEEP 2021. 16 June 2021
Biosimilars
South Korean biosimilars specialist Celltrion Healthcare has presented new Phase IV data for Truxima (rituximab-abbs) at the annual meeting of the European Hematology Association (EHA). 14 June 2021
Biotechnology
Positive follow-up results from the pivotal ZUMA-5 trial of Yescarta (axicabtagene ciloleucel) - the first and only CAR T-cell therapy approved in the USA in patients with relapsed or refractory indolent follicular lymphoma (FL) - were presented over the weekend at the 26th Annual Meeting of the European Hematology Association (EHA 2021) now taking place virtually. 14 June 2021
Biotechnology
US biotech Protagonist Therapeutics saw its shares gain 17% to $39.64 on Friday, after it announced updated results from the ongoing Phase II study of rusfertide (PTG-300), an investigational new drug being evaluated for the treatment of polycythemia vera (PV), a type of blood cancer. 12 June 2021
Biotechnology
Sino-American biotech BeiGene’s shares edged up 3% to HK$216.4% on Friday, after it presented results from the interim analysis of the Phase III ALPINE trial comparing its BTK inhibitor Brukinsa (zanubrutinib) to ibrutinib. 12 June 2021
Biotechnology
Swiss pharma giant Roche today announced the latest data from three pivotal Phase III studies of Venclexta/Venclyxto (venetoclax) – CLL14, MURANO and VIALE-A – at the European Hematology Association Virtual Congress, June 9-17 (EHA2021). 11 June 2021
Biotechnology
French pharma major Sanofi is presenting results from Part A of CADENZA, a pivotal Phase III double-blind, placebo-controlled study evaluating the safety and efficacy of sutimlimab in people with cold agglutinin disease (CAD) without a recent history of blood transfusion (within the prior six months), at an oral session of the European Hematology Association (EHA) 2021 Congress now taking place virtually. 11 June 2021
Pharmaceutical
Basel-based pharma giant Roche has announced new interim data from two studies of Evrysdi (risdiplam), JEWELFISH and RAINBOWFISH. 11 June 2021
Pharmaceutical
The Franco-American pairing of Ipsen and Exelixis have announced detailed results from the Phase III COSMIC-311 pivotal trial of Cabometyx (cabozantinib) in previously-treated radioactive iodine-refractory differentiated thyroid cancer. 9 June 2021
Biotechnology
New research led by the Roswell Park Comprehensive Cancer Center in Buffalo, USA, shows that treatment with checkpoint blockers has led to a significant improvement among people with a certain type of kidney cancer. 8 June 2021
Pharmaceutical
Japanese pharma giant Takeda Pharmaceutical has detailed positive results from a new subgroup analysis of the Phase III SOLSTICE trial of maribavir. 8 June 2021
Biotechnology
Russian pharma company R-Pharm has highlighted the views of four leading rheumatologists on its rheumatoid arthritis (RA) drug candidate olokizumab, which successfully completed international Phase III trials in 2020. 7 June 2021
Biotechnology
Chinese biopharma BeiGene has announced data from two pivotal trials of its anti-PD-1 antibody tislelizumab at the 2021 American Society of Clinical Oncology Annual Meeting (ASCO 2021). 7 June 2021
Pharmaceutical
French pharma major Sanofi presented new data for its oral selective estrogen receptor degrader (SERD), amcenestrant, in combination with Ibrance (CDK4/6 inhibitor), at this year’s meeting of the American Society for Clinical Oncology (ASCO). 7 June 2021
Biotechnology
At the annual meeting of the American Society of Clinical Oncology, Gilead Sciences subsidiary Kite has presented encouraging data from a primary analysis of the Phase I/II ZUMA-3 trial. 7 June 2021
Biotechnology
Swiss pharma giant Roche today announced new data on its investigational CD20xCD3 T-cell engaging bispecific antibodies, mosunetuzumab and glofitamab, and its first-in-class anti-CD79b antibody-drug conjugate, Polivy (polatuzumab vedotin), in non-Hodgkin lymphoma (NHL) that are being presented at the 2021 ASCO Annual Meeting. 4 June 2021
Pharmaceutical
AstraZeneca and Merck & Co’s Lynparza (olaparib) has become the first drug targeting BRCA mutations to show clinical benefit in the adjuvant setting. 4 June 2021
Biotechnology
China’s Shanghai Junshi Biosciences and US biosimilars company Coherus BioSciences have released positive results from the pivotal study JUPITER-02, a randomized, double-blind, placebo-controlled Phase III clinical trial evaluating toripalimab plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC). 4 June 2021
Biotechnology
Swiss pharms giant Novartis has announced that results of the Phase III VISION study evaluating 177Lu-PSMA-617, a targeted radioligand therapy, plus best standard of care (SOC) demonstrated significant improvement in overall survival (OS) compared to SOC alone, in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). 4 June 2021
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze